Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere®) in the UK

Annals of Oncology

Volumn 10, Issue 2, 1999, Pages 205-210

  O'Brien, M E R ^d   Leonard, R C ^c   Barrett Lee, P J ^d   Eggleton, S P H ^a   Bizzari, J P ^b  

^a Rhone Poulene Rorer Ltd   (United Kingdom)

^b SANOFI   (France)

^c NHS LOTHIAN   (United Kingdom)

^d NONE

Author keywords

Breast cancer; Docetaxel

Indexed keywords

ANTHRACYCLINE; CORTICOSTEROID; DOCETAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROPATHY; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0032991996     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008370930599     Document Type: Article

References (11)

1. Cancer Research Campaign, Factsheet 1997 'Breast Cancer'.
2. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994; 74: 416-23.
3. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44: 17-28.
4. Leonard RCF, Rodger A, Dixon JM. ABC of breast disease. Melastic breast cancer. BMJ 1994; 309: 1501-4.
5. Henderson IC. Principles in the management of metastatic disease, chemotherapy for metastatic disease. In Harris JR, Hellman S. Henderson IC et al. (eds): Breast Diseases. Philadelphia, PA: Lippincott 1991; 604-65.
6. Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94.
7. Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): Single-agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev 1995; 21: 463-78.
8. Van Oosterom AT. Docetaxel (Taxotere): An effective agent in the management of second-line breast cancer. Semin Oncol 1995; 22: 22-8.
9. Ten Bokkel-Huinink WW, Prove AM, Piccard M et al. A phase II trial with docetaxel (Taxotere) in second-line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 527-32.
10. Ravdin PM, Burris HA, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85.
11. Guastalla JP, Bonneterre J, Fumoleau P et al. A phase II trial of docetaxel in patients (pts) with anthracycline-resistant (AR) metastatic breast cancer (MBC). Eur J Cancer 1995; (Suppl 5): in press.